A Randomized Phase II Study of Tecemotide in Combination With Standard Androgen Deprivation Therapy and Radiation Therapy for Untreated, Intermediate and High Risk Prostate Cancer Patients

Trial Profile

A Randomized Phase II Study of Tecemotide in Combination With Standard Androgen Deprivation Therapy and Radiation Therapy for Untreated, Intermediate and High Risk Prostate Cancer Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Tecemotide (Primary) ; Goserelin
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Sponsors EMD Serono
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 Feb 2017 Preliminary results evaluating predictive role of apparent diffusion coefficient on MRI for assessing immunologic impact, presented at the 2017 Genitourinary Cancers Symposium
    • 15 Feb 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top